Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fritz Offner

Showing results (71-80 of 126) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA TrialClémentine Sarkozy, Marek Trneny, Luc Xerri, et al.
The Lancet. Haematology|December 11, 2025
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trialArnon P Kater, Ann Janssens, Herbert Eradat, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Cancers|April 3, 2021
Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 CellsEmilie Logie, Chandra S Chirumamilla, Claudina Perez-Novo, et al.
Cancer Medicine|February 24, 2018
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studiesAurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
Pageof 13

Showing results (71-80 of 126) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA TrialClémentine Sarkozy, Marek Trneny, Luc Xerri, et al.
The Lancet. Haematology|December 11, 2025
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trialArnon P Kater, Ann Janssens, Herbert Eradat, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Cancers|April 3, 2021
Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 CellsEmilie Logie, Chandra S Chirumamilla, Claudina Perez-Novo, et al.
Cancer Medicine|February 24, 2018
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studiesAurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
Pageof 13